

Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) + chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in RATIONALE-305

Authors: Evaristo Maiello,¹ Marcia Cruz Correa,² Rui-Hua Xu,³ Markus Moehler,⁴ Do-Youn Oh,⁵ Ken Kato,⁶ David Spigel,⁷ Hendrik-Tobias Arkenau,⁸ Josep Tabernero,⁹ Anastasia V. Zimina,¹⁰ Yuxian Bai,¹¹ Jianhua Shi,¹² Keun-Wook Lee,¹³ Hidekazu Hirano,⁶ Lucjan Wyrwicz,¹⁴ Roberto Pazo Cid,¹⁵ Hui Xu,¹⁶ Tao Sheng,¹⁶ Gisoo Barnes¹⁷

Affiliations: ¹Foundation IRCCS Casa Sollievo della Sofferenza, Oncology Unit, San Giovanni Rotondo, Italy; ²University of Puerto Rico, School of Medicine, San Juan, Puerto Rico; ³University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of Medical Oncology, Guangzhou, China; ⁴Johannes Gutenberg-University Clinic, Department of Internal Medicine I, Mainz, Germany; ⁵Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Republic of Korea; ⁶National Cancer Center Hospital, Department of Gastrointestinal Medical Oncology, Tokyo, Japan; ⁷Sarah Cannon Research Institute, Nashville, TN, USA; ⁸Sarah Cannon Research, London, United Kingdom; ⁹Vall d'Hebron University Hospital, Department of Medical Oncology, Barcelona, Spain; ¹⁰BIH of Omsk Region, Clinical Oncology Dispensary, Omsk Oblast, Russia; ¹¹Harbin Medical University Cancer Hospital, Department of Gastrointestinal Oncology, Harbin, China; ¹²Linyi Cancer Hospital, Department II of Medical Oncology, Linyi, China; ¹³Seoul National University College of Medicine, Seoul National University Bundang Hospital, Department of Medical Oncology (Internal Medicine), Seongnam, Republic of Korea; ¹⁴Maria Sklodowska-Curie National Cancer Research Institute, Department of Oncology and Radiotherapy, Warsaw, Poland; ¹⁵Hospital Universitario Miguel Servet, Department of Medical Oncology, Zaragoza, Spain; ¹⁶BeiGene (Beijing) Co., Ltd., Beijing, China; ¹⁷BeiGene USA, Inc., San Mateo, CA, USA

ABSTRACT

Background: RATIONALE-305 (NCT03777657) showed statistically significant and clinically meaningful improvements in overall survival (OS) with TIS+chemo (n=501) over PBO+chemo (n=496) as 1L treatment in patients (pts) with advanced GC/GEJC. We examined HRQoL in RATIONALE-305 at final analysis.

Materials (Patients) and Methods: Adults with previously untreated, unresectable, or metastatic GC/GEJC, were randomized (1:1) to TIS 200 mg or PBO IV once every 3 weeks plus investigator-choice of chemo. HRQoL was assessed using EORTC QLQ-C30 and the QLQ-STO22. A mixed model for repeated measures of PRO endpoints at Cycles 4 and 6 was performed. Time-to-deterioration was examined.

Results: TIS+chemo had improved outcomes (least-square mean change from baseline) vs PBO+chemo (Table) as indicated by the estimated mean treatment difference at Cycle 6 for QLQ-C30 GHS/QoL (2.52 [95% CI, 0.29-4.74]), physical functioning (2.46 [95% CI, 0.49-4.43]), fatigue (-3.01 [95% CI, -5.78 to -0.24]), and STO22 index score (-1.62 [95% CI, -3.12 to -0.12]), and maintaining upper gastrointestinal (GI) symptoms (-1.74 [95% CI, -3.55 to 0.06]) and pain (-1.88 [95% CI, -4.03 to 0.27]). Pts receiving TIS+chemo had lower risk of deterioration of GHS/QoL (HR, 0.77 [0.60-0.98]), physical functioning (HR, 0.72 [0.57-0.92]), STO22 index score (HR, 0.64 [0.45-0.92]), pain/discomfort (HR, 0.74 [0.58-0.96]), and upper GI symptoms (HR, 0.73 [0.56-0.95]).

Conclusion: The TIS+chemo group had better HRQoL outcomes vs the PBO+chemo group, particularly for GHS/QoL, physical functioning, fatigue, GC/GEJC symptoms, pain/discomfort, and upper GI symptoms. These results, along with prolonging of OS and other secondary efficacy endpoints, and tolerable safety, support the benefit of TIS+chemo as a potential 1L treatment option for GC/GEJC.

	Cycle 6 TIS+Chemo n=501 Mean (95% CI)	Cycle 6 PBO+Chemo n=496 Mean (95% CI)
QLQ-C30		
GHS/QoL	0.93 (-0.71, 2.57)	-1.58 (-3.24, 0.07)
Physical functioning	-2.76 (-4.22, -1.30)	-5.22 (-6.69, -3.75)
Fatigue	1.71 (-0.32, 3.75)	4.73 (2.68, 6.77)
QLQ-STO22		
Index score	-1.84 (-2.95, -0.74)	-0.22 (-1.34, 0.89)
Dysphagia	-2.79 (-3.93, -1.64)	-2.01 (-3.17, -0.86)
Pain/discomfort	-5.97 (-7.56, -4.38)	-4.09 (-5.69, -2.49)
Dietary restrictions	-0.25 (-1.79, 1.30)	1.08 (-0.48, 2.63)
Upper GI symptoms	-3.24 (-4.58, -1.90)	-1.49 (-2.84, -0.14)